Search

Your search keyword '"Yasunari, Kenichi"' showing total 218 results
Start Over Author "Yasunari, Kenichi"
218 results on '"Yasunari, Kenichi"'

66. Vascular Dopamine-I Receptors

Author

Yasunari, Kenichi, primary, Kohno, Masakazu, additional, Yokokawa, Koji, additional, Horio, Takeshi, additional, Kano, Hiroaki, additional, and Takeda, Tadanao, additional

Published
1995
Full Text
View/download PDF

68. Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty

Author

Horio, Takeshi, primary, Shimada, Ken-ei, additional, Kohno, Masakazu, additional, Yoshimura, Takayoshi, additional, Kawarabayashi, Takahiko, additional, Yasunari, Kenichi, additional, Murakawa, Koh-ichi, additional, Yokokawa, Koji, additional, Ikeda, Miwako, additional, Fukui, Toshiki, additional, and Takeda, Tadanao, additional

Published
1993
Full Text
View/download PDF

78. Endothelin-Secreting Tumor

Author

Yokokawa, Koji, primary, Tahara, Hideki, additional, Kohno, Masakazu, additional, Murakawa, Koh-ichi, additional, Yasunari, Kenichi, additional, Nakagawa, Koichi, additional, Hamada, Toshio, additional, Otani, Shuzo, additional, Yanagisawa, Masashi, additional, and Takeda, Tadanao, additional

Published
1991
Full Text
View/download PDF

85. Pharmacological and Clinical Studies with Temocapril, an Angiotensin Converting Enzyme Inhibitor that is Excreted in the Bile.

Author

Yasunari, Kenichi, Maeda, Kensaku, Nakamura, Munehiro, Watanabe, Takanori, Yoshikawa, Junichi, and Asada, Akira

Abstract

ABSTRACT Temocapril is an angiotensin converting enzyme inhibitor (ACEI), a prodrug with a thiazepine ring. Its active form, temocaprilat, is slightly more potent than enalaprilat in inhibiting ACE isolated from rabbit lung. The inhibitory potency of temocaprilat on isolated rat aorta is 3 times that of enalaprilat. Temocapril is excreted in the bile and urine and can be used in patients with renal insufficiency. It reduces blood pressure without causing any significant change in heart rate or cardiac output. Temocapril has been reported to improve endothelial dysfunction in vitro by suppressing increased oxidative stress. In vivo it improves reactive hyperemia in patients with essential hypertension. It has been reported to prevent coronary vascular remodeling in vivo by suppressing local ACE and increased oxidative stress. In humans temocapril has been found to improve insulin resistance partly by increasing adiponectin levels. Cardiac remodeling was improved by temocapril not only in experiment animals but also in humans. It improves renal function and decreases urinary albumin excretion in diabetics as well as in hypertensive patients. Temocapril is currently marketed only in Japan. Considering its beneficial effects and unique pharmaco-kinetics, temocapril, is likely to be introduced in other countries as well. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

87. ANTI-ATHEROSCLEROTIC ACTION OF VASCULAR D1 RECEPTORS.

Author

Yasunari, Kenichi, Kohno, Masakazu, Kano, Hiroaki, Hanehira, Takao, Minami, Mieko, and Yoshikawa, Junichi

Subjects
*DOPAMINE receptors, *ATHEROSCLEROSIS, *VASCULAR smooth muscle, *CELL proliferation, *PROTEIN kinases
Abstract

1. Vascular smooth muscle cell (VSMC) migration and proliferation are believed to play key roles in atherosclerosis. To elucidate the role of vascular dopamine D1-like (D1 and D5) receptors in atherosclerosis, the effects of dopamine and the specific D1-like receptor agonists SKF 38393 and YM 435 on platelet-derived growth factor (PDGF)-BB-mediated VSMC migration, proliferation and hypertrophy were investigated. 2. We observed that cells stimulated by 5 ng/mL PDGF-BB showed increased migration, proliferation and hypertrophy. These effects were prevented by co-incubation with dopamine, SKF 38393 or YM 435 at 1–10 μmol/L and this prevention was reversed by Sch 23390 (1–10 μmol/L), a specific D1-like receptor antagonist. These actions of D1-like receptor agonists were mimicked by 1–10 μmol/L forskolin, a direct activator of adenylate cyclase, and 0.1–1 mmol/L 8-bromo-cAMP. The actions were blocked by the specific protein kinase A (PKA) inhibitor N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinoline-sulphonamide (H 89), but were not blocked by its negative control N- [2-(N-formyl-p-chlorocinnamylamino) ethyl]-5-isoquinoline sulphonamide (H 85). Platelet-derived growth factor-BB (5 ng/mL)-mediated activation of phospholipase D (PLD), protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) activity was significantly suppressed by co-incubation with dopamine. 3. These results suggest that vascular D1-like receptor agonists inhibit migration, proliferation and hypertrophy of VSMC, possibly through the activation of PKA and the suppression of activated PLD, PKC and MAPK activity. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

95. Decreased water and potassium content in erythrocytes in essential hypertension.

Author

KAWARABAYASHI, TAKAHIKO, KANAYAMA, YOSHIHARU, TAKEUCHI, KAZUHIDE, OKU, HISAO, KOHNO, MASAKAZU, YOSHIMURA, TAKAYOSHI, YASUNARI, KENICHI, TAKEDA, TADANAO, KAGEYAMA, KATSUHIRO, KINOSHITA, YOSHIHIRO, Kawarabayashi, T, Kanayama, Y, Takeuchi, K, Oku, H, Kohno, M, Yoshimura, T, Yasunari, K, Takeda, T, Kageyama, K, and Kinoshita, Y

Published
1986

Catalog

Books, media, physical & digital resources
See catalog results